| __timestamp | BioCryst Pharmaceuticals, Inc. | Galapagos NV |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 111110000 |
| Thursday, January 1, 2015 | 72758000 | 129714000 |
| Friday, January 1, 2016 | 61008000 | 139574000 |
| Sunday, January 1, 2017 | 66962000 | 218502000 |
| Monday, January 1, 2018 | 84888000 | 322876000 |
| Tuesday, January 1, 2019 | 107068000 | 427320000 |
| Wednesday, January 1, 2020 | 122964000 | 523667000 |
| Friday, January 1, 2021 | 208808000 | 491707000 |
| Saturday, January 1, 2022 | 253297000 | 515083000 |
| Sunday, January 1, 2023 | 216566000 | 241294000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Galapagos NV and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments.
Galapagos NV has consistently increased its R&D budget, peaking in 2020 with a remarkable 370% increase from 2014. This upward trend underscores the company's aggressive pursuit of groundbreaking therapies.
BioCryst Pharmaceuticals, on the other hand, saw a significant surge in R&D spending, particularly between 2019 and 2022, where it nearly doubled its investment. This strategic boost highlights BioCryst's focus on expanding its pipeline and enhancing its competitive edge.
As these companies continue to innovate, their R&D investments will be crucial in shaping the future of biotech breakthroughs.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: argenx SE vs BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Galapagos NV
Analyzing R&D Budgets: Verona Pharma plc vs Galapagos NV
Analyzing R&D Budgets: Amneal Pharmaceuticals, Inc. vs Galapagos NV
Comparing Innovation Spending: Apellis Pharmaceuticals, Inc. and Galapagos NV
CRISPR Therapeutics AG vs Galapagos NV: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Agios Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.